Market research
EVG.LSE Evgen Pharma plc
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 11
- Dividend yield
- Not available
- Beta
- 1.44
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BSVYN304
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 11
- Dividend yield
- Not available
- Beta
- 1.44
About
About Evgen Pharma plc
Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EVG.LSE discussion.
5 years, 5 months ago
Evgen Pharma plc is currently in a long term downtrend where the price is trading 18.2% below its 200 day moving average.
From a valuation standpoint, the stock is 87.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 54.6.
Its net income has dropped by 0.0% to $-802K since the same quarter in the previous year.
Finally, its free cash flow fell by 16.8% to $-968K since the same quarter in the previous year.
Based on the above factors, Evgen Pharma plc gets an overall score of 1/5.